Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 7/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29392834 | 1.00 | DGAT1 (0.45) | DGAT1ALOX5APFEN1CCNCCDK8 | |
| SCHEMBL25249478 | 0.89 | DGAT1 (0.42) | DGAT1ALOX5APFEN1CCNCCDK8 | |
| SCHEMBL30531855 | 0.84 | DGAT1 (0.37) | DGAT1ALOX5APFEN1 | |
| SCHEMBL30531851 | 0.82 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL30531846 | 0.81 | DGAT1 (0.37) | DGAT1ALOX5APFEN1 | |
| SCHEMBL25284186 | 0.81 | DGAT1 (0.41) | DGAT1ALOX5APFEN1CCNCCDK8 | |
| SCHEMBL25239322 | 0.81 | DGAT1 (0.41) | DGAT1ALOX5APFEN1CCNCCDK8 | |
| SCHEMBL29394926 | 0.81 | DGAT1 (0.41) | DGAT1ALOX5APFEN1CCNCCDK8 | |
| SCHEMBL25760802 | 0.81 | DGAT1 (0.48) | DGAT1ALOX5APFEN1 | |
| SCHEMBL25237150 | 0.81 | DGAT1 (0.36) | DGAT1ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4192831-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250177362-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20240376061-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-11-14 | — | — | US | disclosed |
| US-11897851-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| CN-116323599-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | DGAT1 534/4885ALOX5AP 2181/4885FEN1 4657/4885 |
| US-11897851-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | DGAT1 534/4885ALOX5AP 2181/4885FEN1 4657/4885 |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, VIP | DGAT1 3133/4885ALOX5AP 4582/4885FEN1 4859/4885 |
| US-20250177362-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, IAPP | DGAT1 302/4885ALOX5AP 1728/4885FEN1 4586/4885 |
| US-20240376061-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | DGAT1 534/4885ALOX5AP 2181/4885FEN1 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.